Artelo Biosciences to Present at the 6th Cannabinoid-Derived Drug Development Summit on September 12th

2 years ago

SOLANA BEACH, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling…

Capricor Therapeutics Appoints Michael Kelliher to Board of Directors

2 years ago

SAN DIEGO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development…

Heart Centre Rigshospitalet Enhances Leadership in Patient Care with Adoption of Latest Robotic Technology

2 years ago

ST. LOUIS, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for…

PharmAla Begins Trading on OTCQB

2 years ago

VANCOUVER, British Columbia, Sept. 06, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB:PMBHF),…

Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12th

2 years ago

HAMILTON, BERMUDA , Sept. 06, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company…

Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease

2 years ago

– Lead program, GT-2108 for the treatment of moderate-to-severe ulcerative colitis advancing toward completion of I ND-enabling studies with IND…

BioHarvest Announces August 2023 U.S. VINIA Sales Exceeded USD $1Million

2 years ago

Significant milestone demonstrating sales momentum of VINIA®Further validation of the Botanical Synthesis Technology PlatformStrong justification of the Direct-to-Consumer sales strategyVancouver,…

Izotropic Files Class II Pre-Submission with FDA & Releases Details on Predicate Devices

2 years ago

Vancouver, British Columbia--(Newsfile Corp. - September 6, 2023) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the…

Awakn Life Sciences Submits Clinical Trial Application for Phase III Trial of AWKN-P001

2 years ago

AWKN-P001 is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for the Treatment of Severe Alcohol Use DisorderToronto,…

International Experts Highlight Demand for Diagnostic Innovations as PenKid’s Research and Real-World Data Fuels Quest for Improved RRT Liberation Tools

2 years ago

International experts recognize the need for diagnostic innovations to support more informed and standardized decisions for liberation from renal replacement…